SMN dysfunction in FUS-dependent ALS
SMN dysfunction in FUS-dependent ALS
批准号:
9329512
负责人:
Livio Pellizzoni
金额:
$20.0万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-08-15 至 2019-07-31
关键词:
AddressAdolescentAdultAgeAllelesAmyotrophic Lateral SclerosisAnabolismAnimal ModelBiogenesisBiological AssayBiological ModelsBiologyBirthCell modelCessation of lifeChildCodeComplexDefectDenervationDiseaseDisease PathwayES Cell LineEtiologyEvaluationEventFamilial Amyotrophic Lateral SclerosisFibroblastsFoundationsFunctional disorderGene DeliveryGenesGeneticGenotypeHistonesHumanIn VitroInduced MutationInfant MortalityInjection of therapeutic agentKnowledgeLasersLinkMammalian CellMediatingMendelian disorderMessenger RNAMicrodissectionMinorityModelingMolecularMonitorMorphologyMotorMotor Neuron DiseaseMotor NeuronsMusMutant Strains MiceMutationNatureNerve DegenerationNervous system structureNuclearPathogenesisPathogenicityPathologyPathway interactionsPatientsPhenotypePropertyProtein IsoformsRNARNA ProcessingRNA SplicingRNA-Binding ProteinsRiskRoleSMN protein (spinal muscular atrophy)SMN1 geneSeriesSeverity of illnessSmall Nuclear RNASmall Nuclear RibonucleoproteinsSolidSpinalSpinal CordSpinal Muscular AtrophyTestingToxic effectTransgenic MiceWorkbehavior testclinical phenotypedefined contributiondesignexperimental studygain of functiongene producthuman diseaseinterdisciplinary approachmRNA Precursormotor disordermotor neuron degenerationmotor neuron functionmouse modelmutantnervous system disorderneuromuscularnoveloverexpressionsarcomaskeletal muscle wastingsurvival motor neuron genetherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are fatal neurological disorders that
involve the selective degeneration of spinal motor neurons. SMA – the most common genetic cause of infant
mortality – is a monogenic disorder caused by widespread deficiency in the survival motor neuron (SMN)
protein due to deletion of the SMN1 gene. In contrast, ALS is predominantly a sporadic disorder, but in a
minority of familial cases, mutations in over 20 different genes cause motor neuron degeneration. Genetic and
molecular studies increasingly suggest that ALS and SMA may share common underlying mechanisms of
disease. This project focuses on one form of familial ALS caused by mutations in the RNA binding protein
fused in sarcoma (FUS) - which are associated with a broad range of clinical phenotypes including some of the
most aggressive, juvenile-onset forms of the disease - and the possible role of SMN biology in the
pathogenesis of FUS-dependent motor neuron degeneration. SMN has a well-established function in the
assembly of small nuclear ribonucleoproteins (snRNPs) involved in diverse mRNA processing pathways and
increasing evidence links SMN-dependent RNA dysregulation with the etiology of SMA. Remarkably, recent
studies in cultured mammalian cells and ALS patients' fibroblasts have shown that FUS depletion or
expression of ALS-linked FUS mutations disrupt the normal localization of SMN to nuclear bodies known as
Gems. Furthermore, FUS has been shown to associate with SMN as well as specific snRNPs whose
biogenesis is SMN-dependent and might be disrupted by ALS-linked FUS mutations. Together, these findings
suggest that FUS and SMN are functionally linked through a shared molecular pathway(s) and support the
view that SMA and ALS are related motor neuron diseases. However, the normal requirement of FUS for
snRNP biogenesis and the pathogenic impact of FUS mutations on SMN biology have not yet been defined
mechanistically, and the contribution of SMN dysfunction to FUS-ALS pathology remains unknown. To address
these outstanding questions directly, our project takes a systematic, multi-disciplinary approach involving novel
mouse models of FUS-dependent ALS to explore potential SMN-dependent mechanisms of FUS-mediated
motor neuron degeneration. In Aim 1, we will investigate the phenotypic effects of both reduced and increased
SMN expression on FUS-dependent motor neuron pathology in mouse models of ALS. In Aim2, we will employ
a comprehensive set of molecular approaches to establish the functional relevance of normal and pathogenic
FUS-SMN interactions in the pathway(s) of snRNP biogenesis in motor neurons using a combination of cellular
and animal model systems. Collectively, these studies aim to establish convergent mechanisms in ALS and
SMA and will yield a more complete understanding of the biology of FUS and SMN that is relevant to motor
neuron survival. Identification of shared molecular pathways contributing to death and dysfunction of motor
neurons in SMA and ALS may also expand the range of therapeutic targets for these diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms and therapeutic targeting of motor neuron death in SMA
-
批准号:10334501
-
项目类别:
-
资助金额:$47.23万
-
财政年份:2020
-
负责人:Livio Pellizzoni
-
依托单位:
Mechanisms and therapeutic targeting of motor neuron death in SMA
-
批准号:10559530
-
项目类别:
-
资助金额:$47.23万
-
财政年份:2020
-
负责人:Livio Pellizzoni
-
依托单位:
Mechanisms and therapeutic targeting of motor neuron death in SMA
-
批准号:10087983
-
项目类别:
-
资助金额:$47.23万
-
财政年份:2020
-
负责人:Livio Pellizzoni
-
依托单位:
Essential role of Stasimon in motor circuit development and disease
-
批准号:10312031
-
项目类别:
-
资助金额:$58.18万
-
财政年份:2019
-
负责人:Livio Pellizzoni
-
依托单位:
Essential role of Stasimon in motor circuit development and disease
-
批准号:10531553
-
项目类别:
-
资助金额:$58.18万
-
财政年份:2019
-
负责人:Livio Pellizzoni
-
依托单位:
Essential role of Stasimon in motor circuit development and disease
-
批准号:10057404
-
项目类别:
-
资助金额:$58.18万
-
财政年份:2019
-
负责人:Livio Pellizzoni
-
依托单位:
RNA-mediated mechanisms of motor system dysfunction in spinal muscular atrophy
-
批准号:10022699
-
项目类别:
-
资助金额:$1.74万
-
财政年份:2019
-
负责人:Livio Pellizzoni
-
依托单位:
The Role of p38 MAPK Activation in Spinal Muscular Atrophy
-
批准号:9317946
-
项目类别:
-
资助金额:$24.0万
-
财政年份:2017
-
负责人:Livio Pellizzoni
-
依托单位:
SMN dysfunction in FUS-dependent ALS
-
批准号:9227825
-
项目类别:
-
资助金额:$24.0万
-
财政年份:2016
-
负责人:Livio Pellizzoni
-
依托单位:
A genome-wide phenotypic screen for modifiers of SMN expression and function
-
批准号:8702410
-
项目类别:
-
资助金额:$24.0万
-
财政年份:2014
-
负责人:Livio Pellizzoni
-
依托单位:
Small chemical modulators of SMN biology as candidate therapeutics for SMA
-
批准号:8702663
-
项目类别:
-
资助金额:$32.0万
-
财政年份:2014
-
负责人:Livio Pellizzoni
-
依托单位:
Role of Stasimon Dysfunction in Spinal Muscular Atrophy
-
批准号:8303810
-
项目类别:
-
资助金额:$24.0万
-
财政年份:2012
-
负责人:Livio Pellizzoni
-
依托单位:
Role of Stasimon Dysfunction in Spinal Muscular Atrophy
-
批准号:8413610
-
项目类别:
-
资助金额:$19.3万
-
财政年份:2012
-
负责人:Livio Pellizzoni
-
依托单位:
SMN Control of snRNP Biogenesis: Role in RNA Splicing and Motor Neuron Survival
-
批准号:8241047
-
项目类别:
-
资助金额:$34.51万
-
财政年份:2010
-
负责人:Livio Pellizzoni
-
依托单位:
SMN Control of snRNP Biogenesis: Role in RNA Splicing and Motor Neuron Survival
-
批准号:8056786
-
项目类别:
-
资助金额:$34.51万
-
财政年份:2010
-
负责人:Livio Pellizzoni
-
依托单位:
A Functional Cell-Based Screen for Potential SMA Therapeutic Compounds
-
批准号:7978376
-
项目类别:
-
资助金额:$20.13万
-
财政年份:2010
-
负责人:Livio Pellizzoni
-
依托单位:
SMN Control of snRNP Biogenesis: Role in RNA Splicing and Motor Neuron Survival
-
批准号:8434228
-
项目类别:
-
资助金额:$33.31万
-
财政年份:2010
-
负责人:Livio Pellizzoni
-
依托单位:
SMN Control of snRNP Biogenesis: Role in RNA Splicing and Motor Neuron Survival
-
批准号:8629797
-
项目类别:
-
资助金额:$34.17万
-
财政年份:2010
-
负责人:Livio Pellizzoni
-
依托单位:
A Functional Cell-Based Screen for Potential SMA Therapeutic Compounds
-
批准号:8109329
-
项目类别:
-
资助金额:$23.67万
-
财政年份:2010
-
负责人:Livio Pellizzoni
-
依托单位:
SMN Control of snRNP Biogenesis: Role in RNA Splicing and Motor Neuron Survival
-
批准号:7863137
-
项目类别:
-
资助金额:$34.39万
-
财政年份:2010
-
负责人:Livio Pellizzoni
-
依托单位:
海外基金